Work Ability After Diagnosis in Survivors of Hodgkin Lymphoma
Researchers sought to determine the work ability for survivors of Hodgkin lymphoma after diagnosis.
Diagnosis & Disease Information
ASCO 2023: Lymphoma Research Could Change Practice
Studies presented at the ASCO Annual Meeting 2023 highlighted new developments in lymphoma that could lead to changes in practice.
BrECADD Noninferior to eBEACOPP in Patients With Advanced-Stage Classical Hodgkin Lymphoma
Researchers sought to determine whether BrECADD would be as effective as eBEACOPP in patients with advanced-stage classical Hodgkin lymphoma.
Intensified ABVD Bests PET-Adapted ABVD as First-Line Therapy for Hodgkin Lymphoma
Intensified ABVD can improve outcomes, when compared with PET-adapted ABVD, in patients with previously untreated Hodgkin lymphoma, a phase 3 study suggests.
Brentuximab Vedotin Plus Nivolumab, Doxorubicin, and Dacarbazine Shows Promising Activity in Early-Stage cHL
Researchers sought to determine whether adding brentuximab vedotin to nivolumab, doxorubicin, and dacarbazine would be a helpful first-line treatment for cHL.
Superior PFS Seen With Nivolumab vs Brentuximab Vedotin in Advanced-Stage cHL
Researchers sought to determine whether nivolumab would improve PFS compared with brentuximab vedotin in patients with advanced-stage cHL.
High CMR Rates Seen With Nivolumab Plus Brentuximab Vedotin in CAYA Relapsed/Refractory Hodgkin Lymphoma
Researchers sought to determine whether combining nivolumab plus brentuximab vedotin would improve response rates in CAYAs with Hodgkin lymphoma.
Survey Shows Oncologists Vary in Guideline Adherence for PET-Adapted Approaches in Classic Hodgkin Lymphoma
Researchers sought to determine adherence to guidelines for oncologists utilizing PET-adapted strategies for patients with III/IV classic Hodgkin lymphoma.
Patients With RA May Safely Receive ICIs for Cancer Treatment
Researchers studied the effect of preexisting rheumatoid arthritis on risk for mortality and immune-related adverse events among those receiving immune checkpoint inhibitors.
Pembrolizumab Plus ICE Deemed Effective in Relapsed/Refractory Hodgkin Lymphoma
Pembrolizumab plus ICE chemotherapy appears effective as second-line treatment in patients with transplant-eligible Hodgkin lymphoma.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...